To include your compound in the COVID-19 Resource Center, submit it here.

Eylea aflibercept ophthalmic solution regulatory update

FDA granted breakthrough therapy designation to Eylea aflibercept from Regeneron to treat diabetic retinopathy in patients with diabetic macular

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE